MabThera Approved In Europe For Non-Hodgkin's Lymphoma
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




MabThera Approved In Europe For Non-Hodgkin's Lymphoma

SAN DIEGO, CA -- June 3, 1998 -- The European Commission has granted marketing authorisation to F. Hoffmann-LaRoche’s MabThera® (rituximab) for patients suffering from relapsed or chemoresistant follicular B-cell non-Hodgkin’s lymphoma in all European Union countries.

Rituximab is co-promoted in the United States by IDEC Pharmaceuticals Corp. and Genentech under the tradename, Rituxan(TM)

The first monoclonal antibody therapy for the treatment of patients suffering from non-Hodgkin's B-cell lymphoma, MabThera will be available initially to patients in the United Kingdom and Germany, with launch in other member states of the European Union to follow soon afterward.

Rituximab was approved by the U.S. Food and Drug Administration on Nov. 26, 1997. The treatment is indicated for relapsed or refractory low grade or follicular, CD20-positive B-cell non-Hodgkin's lymphoma.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities